Cargando…

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset

BACKGROUND: Standard-dose intravenous alteplase for acute ischemic stroke (AIS) in the unknown or extended time window beyond 4.5 h after symptom onset is both effective and safe for certain patients who were selected based on multimodal neuroimaging. However, uncertainty exists regarding the potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zekun, Ji, Kangxiang, Fang, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175638/ https://www.ncbi.nlm.nih.gov/pubmed/37188314 http://dx.doi.org/10.3389/fneur.2023.1165237

Ejemplares similares

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis
por: Xu, Jiawen, et al.
Publicado: (2023)

Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam
por: Mai, Duy Ton, et al.
Publicado: (2021)

Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h
por: Chen, Chih-Hao, et al.
Publicado: (2022)

Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial
por: Zhou, Zien, et al.
Publicado: (2021)

Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients
por: Salem, Gelan M., et al.
Publicado: (2021)

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials
por: Liang, Huo, et al.
Publicado: (2023)

Low-dose versus standard-dose alteplase for intravenous thrombolysis in patients with acute ischemic stroke in Iran: Results from the safe implementation of treatments in stroke registry
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2021)

Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study
por: Kim, Jong S., et al.
Publicado: (2018)

Impact of Intravenous Alteplase Door-to-Needle Times on 2-Year Mortality in Patients With Acute Ischemic Stroke
por: Bhatt, Nirav R., et al.
Publicado: (2021)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt
por: Aref, Hany, et al.
Publicado: (2023)

IV-Thrombolysis in Ischemic Stroke With Unknown Time of Onset—Safety and Outcomes in Posterior vs. Anterior Circulation Stroke
por: Macha, Kosmas, et al.
Publicado: (2021)

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
por: Zhai, Mingfeng, et al.
Publicado: (2023)

Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials
por: Kobeissi, Hassan, et al.
Publicado: (2023)

Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs
por: Naidech, Andrew M., et al.
Publicado: (2020)

Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
por: Yang, Nan, et al.
Publicado: (2023)

A comparison of low- versus standard-dose bridging alteplase in acute ischemic stroke mechanical thrombectomy using indirect methods
por: Zheng, Wei, et al.
Publicado: (2023)

Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis
por: Tan, Ge, et al.
Publicado: (2017)

Machine Learning-Based Model for Prediction of Hemorrhage Transformation in Acute Ischemic Stroke After Alteplase
por: Xu, Yanan, et al.
Publicado: (2022)

No sex difference was found in the safety and efficacy of intravenous alteplase before endovascular therapy
por: Fang, Min, et al.
Publicado: (2022)

Correlation Between Blood Glucose Variability and Early Therapeutic Effects After Intravenous Thrombolysis With Alteplase and Levels of Serum Inflammatory Factors in Patients With Acute Ischemic Stroke
por: Cai, Yun, et al.
Publicado: (2022)

Association of White Blood Cell Count With Clinical Outcome Independent of Treatment With Alteplase in Acute Ischemic Stroke
por: Barow, Ewgenia, et al.
Publicado: (2022)

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
por: Xu, Na, et al.
Publicado: (2018)

Endovascular Treatment With or Without Prior Intravenous Alteplase for Acute Ischemic Stroke
por: Chalos, Vicky, et al.
Publicado: (2019)

Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator)
por: Filatov, Asia, et al.
Publicado: (2021)

Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial
por: Koga, Masatoshi, et al.
Publicado: (2023)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
por: Shen, Ziyi, et al.
Publicado: (2023)

Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
por: Anderson, Craig S., et al.
Publicado: (2015)

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
por: Chen, Jie, et al.
Publicado: (2022)

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review
por: Potla, Neha, et al.
Publicado: (2022)

Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke
por: Estella, Ángel, et al.
Publicado: (2022)

Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window
por: Pan, Yuanmei, et al.
Publicado: (2021)

Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time
por: McCartney, Peter J., et al.
Publicado: (2020)

Wake-Up Stroke and Stroke of Unknown Onset: A Critical Review
por: Wouters, Anke, et al.
Publicado: (2014)

Safety and Efficacy of Low-Dose Tirofiban Combined With Intravenous Thrombolysis and Mechanical Thrombectomy in Acute Ischemic Stroke: A Matched-Control Analysis From a Nationwide Registry
por: Ma, Gaoting, et al.
Publicado: (2021)

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke
por: Zhai, Mingfeng, et al.
Publicado: (2023)

To Treat or Not to Treat: Low‐Dose Alteplase for Patients With Acute Ischemic Stroke Taking Direct Oral Anticoagulants Within 24 Hours
por: Kam, Wayneho, et al.
Publicado: (2022)

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit
por: Bivard, Andrew, et al.
Publicado: (2022)

Effects of alteplase in the treatment of acute ischemic stroke
por: Yayan, Josef
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c6u7u33itfgnl2q4hnlr2p945r